New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
08:15 EDTSNTISenesco opens two new clinical trial sites, initiates treatment in South Africa
Senesco Technologies reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. Treatment of the first patient in South Africa has been initiated in Senesco’s Phase 1b/2a clinical study of its product candidate, SNS01-T. The study is an open-label, multiple-dose, dose-escalation study, which is evaluating the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma, mantle cell or diffuse large B-cell lymphoma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein in multiple myeloma and CT imaging in MCL and DLBC.
News For SNTI From The Last 14 Days
Check below for free stories on SNTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
08:15 EDTSNTISenesco Technologies to change name to Sevion Therapeutics
Senesco Technologies announced a corporate rebranding under which the company will change its name to Sevion Therapeutics, Inc. The company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the company’s goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use